S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

CRSP stock may offer an intriguing opportunity for investors with a long time horizon 

Shares of CRISPR Therapeutics (NASDAQ: CRSP) are up 4% in 2022. And long-term shareholders who have held their shares in CRSP stock for the last five years have been rewarded with a gain of over 330%. However, the stock is trading nearly 50% below its 52-week high. That means, if you were a shareholder that got in on CRSP stock near its peak, you could have a negative opinion of the stock. 

That's the nature of speculative stocks in areas like gene editing. CRSPR Therapeutics attracted a lot of speculative money on the promise of its CRISPR/Cas9 gene editing platform. But in the flight to safety, investors are fleeing from a company that may be years away from a truly breakthrough product release.  

With all that said, investing in emerging growth stocks such as CRISPR Therapeutics means having belief in the company’s underlying technology. And being willing to hold on to your shares until that belief becomes a reality.  

In this article, I’ll lay out the current state of affairs for CRISPR Therapeutics so you can decide if the company is worth a speculative investment. 

An Investment in the Future of Medicine 

Despite the volatility in the broader market, the gene editing sector has been a consistent source of investor speculation. And CRISPR Therapeutics is a leader in this space. The company is synonymous with transformative medicines through its signature CRISPR/Cas9 gene editing platform.  

CRISPR Therapeutics has a long pipeline that focuses in four primary areas:  


  • Hemoglobinopathies – This is focused on β-thalassemia and sickle cell disease (SCD). Both diseases result from gene mutation. The company’s therapeutics is hoping to alter the current course of lifetime treatment that includes regular transfusions, painful symptoms and chronic hospitalizations 
  • Immuno-Oncology – This area is focusing on developing allogenic CAR-T cells that the company believes will have similar or better efficacy than autologous CAR-T cells that are the current standard of care for many cancers. These would also provide other benefits such as immediate availability, increased potency, and allow for flexible dosing.  
  • Regenerative Medicine – This involves the use of stem cells to “repair or replace tissue or organ function lost due to disease, damage or age...” The company believes this is a field where “compelling clinical proofs of concept” are likely to emerge.  
  • In Vivo – This wil allow the company to use its gene editing platform to systemically or directly into specific target organs. The company believes this can help cure a variety of genetically-defined diseases.  

A Solid Cash Position 

As you can see, the company has a long pipeline that is full of breakthrough potential. However, the reality remains that only a handful of these projects are in the clinical testing phase. That process alone generally takes several years to work through. 

That means it will take years, and plenty of cash, to continue developing these products. The good news for investors is that, as of the company’s last earnings report, it was being a good steward of the cash it had on hand. Specifically, the company had total assets valued at $2.6 billion as opposed to total liabilities of approximately $361 million. This will be something that investors will want to watch when the company reports earnings in August.  

CRSP Stock May Be an Opportunistic Buy 

As I mentioned above, if you’re an existing shareholder in CRSP stock, your feelings about your investment will depend on when you bought. But assuming you don’t have a position, this may be a buying opportunity.  

Currently CRSP stock is trading about 15% below the midpoint of its 52-week range. And analysts tracked by MarketBeat give the stock a price target of $111.27, that implies a 40% upside from the stock’s current level. What makes that number more believable is that is after the stock has received several lower price targets in the last 90 days.  

By way of full disclosure, I’m not a shareholder in CRSP stock. It doesn’t fit my personal investment strategy at this time. But the stock is on my watchlist because I do find the company’s gene editing platform intriguing. As my headline states, this could be a moonshot that’s hiding in plain sight.  

However, the company appears to be several years away from delivering meaningful revenue. And it will be longer than that before the company is profitable. Nevertheless, if you have a high risk tolerance and the ability to wait on a stock that may be years away from delivering on its true potential, CRSP stock may be one to consider.  

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
CRISPR Therapeutics (CRSP)
2.2279 of 5 stars
$72.15+0.6%N/A-8.77Moderate Buy$112.33
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in CRISPR Therapeutics right now?

Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastESG - Profitably Invest Your Values

David McNatt discusses ESG investing and offers ways to avoid pitfalls and to understand exactly what kinds of companies you are buying.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.